Listed on the KOSDAQpress release

Signed a license agreement with European Biopharma(undisclosed) for AR-044 jointly developed with Wellmarkerbio (KR)

Completed Technical evaluation for KOSDAQ Listing (Grade A, A)

Completed Phase 1/2a clinical trials for YBL-006 in Korea, Australia, and Thailand

Pre-IPO funding 8 billion KRW

Patent Application for HLA-G Monoclonal antibody

Patent Application for anti-TGF-β recombinant protein

Registered a US patent for YBL-006 (Acrixolimab)

Technology evaluation for applicability of the technology-based listing scheme

Signed a license agreement with Pierre Fabre for YBL-003press release

Selected as an Excellent Corporate R&D Institute by the Ministry of Science and ICT

Signed a license agreement with Pyxis Oncology for YBL-001 jointly developed with LegoChem Biosciencespress release

Signed a license agreement with 3D Medicines (3D MED) for the China rights of YBL-013press release

Signed a joint R&D agreement with NeoImmuneTech for YBL-018press release

Signed a license agreement on antibody sequence with ViroCure for YBL-006, etc.press release

Signed a license agreement on antibody sequence with GI Innovation for YBL-006, etc.press release

Initiated Phase 1 clinical trials for YBL-006 in Korea, Australia and Thailand

Registered a patent for ALiCE, a bispecific T cell engager platform, in the United States

Received the IR52 Jang Young-shil Award for technological innovation (Minister of Science and ICT)

Series D Funding: Raised 20 billion KRW

Series C Funding: Raised 37.4 billion KRW

Signed a joint R&D agreement with LegoChem Biosciences for YBL-001

Signed a joint R&D agreement with HK inno.N for the discovery of 3 bispecific antibodies

Series A/B Funding: Raised 15 billion KRW

Seed Funding: Obtained 1 billion KRW

Conducted joint research & development with Sanofi Aventis on a targeted antibody therapeutic for liver cancer (until 2014)

Obtained Venture Business and Corporate R&D Institute certifications

Establishment of Y-Biologics, Inc.